யூ மலேரியா நிதி News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Team Europe pledges support for eradicateMalaria
maurice-info.mu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from maurice-info.mu Daily Mail and Mail on Sunday newspapers.
Team Europe pledges support for eradicateMalaria, an initiative aiming to facilitate the development and production of a highly efficacious malaria va
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Private and Public Sector Join Forces Under the Umbrella of the kENUP Foundation: BioNTech Announces Project to Develop the First mRNA-Based Prophylactic Malaria vaccine, and the set-up of Manufacturing Infrastructures in Africa
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Team Europe pledges support for eradicateMalaria, an initiative aiming to facilitate the development and production of a highly efficacious malaria vaccine
africanews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from africanews.com Daily Mail and Mail on Sunday newspapers.
Sanaria researchers make progress in the development of highly protective malaria vaccine
Researchers from Sanaria
® Inc. and the National Institutes of Health (NIH) are making progress in the development of highly protective malaria vaccines.
In an article published today in
Nature, Sanaria s PfSPZ-CVac (CQ) vaccine is reported as being safe and protecting 100% of six subjects against a variant malaria parasite three months after their last dose in the company s Phase 1 safety and efficacy trial. This is the first time complete protection against a variant malaria parasite has ever been achieved that long after vaccine administration.
The variant parasite used in the trial is a Brazilian malaria parasite genetically more variant from the African parasites in the vaccine than 700 malaria parasites from Africa. Protection was achieved at a dose that is 20% of the company s first-generation malaria vaccine dosage.